{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:08:32Z","timestamp":1788772112745,"version":"build-2803163510"},"reference-count":99,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background: Precision oncology has significantly transformed the management of non-small cell lung cancer (NSCLC) through the integration of molecular diagnostics, targeted therapies, and biomarker-driven treatment selection. Advances in next-generation sequencing (NGS) and liquid biopsy have improved the identification of actionable molecular alterations and enabled dynamic monitoring of tumor evolution. Objective: To provide a structured narrative review of current evidence regarding actionable molecular biomarkers, diagnostic methodologies, targeted therapies, and future directions in NSCLC precision oncology, with a specific focus on conceptualizing acquired resistance mechanisms. Methods: A structured narrative literature review was conducted by searching PubMed and Google Scholar for English-language studies published between 2015 and 2026. Eligible publications included clinical trials, cohort studies, translational research, reviews, and clinical guidelines addressing molecular profiling, targeted treatments, diagnostic approaches, and resistance mechanisms in NSCLC. Results: A total of 99 foundational studies and clinical documents were analyzed. Key actionable biomarkers included EGFR (Epidermal Growth Factor Receptor), ALK (Anaplastic Lymphoma Kinase), ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog), RET (Rearranged during Transfection), MET (Mesenchymal\u2013Epithelial Transition Factor), HER2 (Human Epidermal Growth Factor Receptor 2) and NTRK (Neurotrophic Tyrosine Receptor Kinase) alterations, along with emerging targets such as NRG1 (Neuregulin 1) fusions. NGS emerged as the cornerstone of comprehensive molecular profiling, while liquid biopsy enabled longitudinal monitoring of tumor dynamics and resistance development. To organize the biological complexity of treatment failure, acquired resistance mechanisms were categorized into a three-tiered conceptual framework: target-centric genetic evolution (Tier 1), cellular plasticity and intratumoral heterogeneity (Tier 2), and non-genetic\/microenvironmental adaptation (Tier 3). Targeted therapies significantly improved clinical outcomes compared with conventional chemotherapy; however, acquired resistance remained a major challenge across all tiers. Conclusions: Precision oncology in NSCLC is evolving from a biomarker-focused approach toward a dynamic framework integrating molecular diagnostics, targeted therapies, and continuous resistance monitoring. The proposed three-tiered resistance framework provides a structured basis for understanding treatment failure, guiding molecular reassessment at progression, and informing future adaptive therapeutic strategies to improve long-term patient outcomes.<\/jats:p>","DOI":"10.3390\/genes17091076","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:07:06Z","timestamp":1788768426000},"page":"1076","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Oncology in Non-Small Cell Lung Cancer: Integrating Molecular Diagnostics, Targeted Therapies, and Resistance Mechanisms"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8181-0487","authenticated-orcid":false,"given":"Aleksandra","family":"Litkowska","sequence":"first","affiliation":[{"name":"Student Scientific Association, Department of Pneumonology, Oncology and Allergology, Jaczewskiego 8 Street, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1393-3689","authenticated-orcid":false,"given":"Jan","family":"Wojtas","sequence":"additional","affiliation":[{"name":"Student Scientific Association, Department of Pneumonology, Oncology and Allergology, Jaczewskiego 8 Street, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Nadulska","sequence":"additional","affiliation":[{"name":"The microGRAM Student Scientific Association, Department of Pharmaceutical Microbiology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7156-5812","authenticated-orcid":false,"given":"Grzegorz","family":"Kurec","sequence":"additional","affiliation":[{"name":"Student Scientific Association, Department of Pneumonology, Oncology and Allergology, Jaczewskiego 8 Street, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliwia","family":"Burdan","sequence":"additional","affiliation":[{"name":"Student Scientific Association, Department of Pneumonology, Oncology and Allergology, Jaczewskiego 8 Street, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142 Adam","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Immunology and Genetics Laboratory, Department of Internal Disease, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-022-00355-7","article-title":"The key to immunotherapy: How to choose better therapeutic biomarkers for patients with non-small cell lung cancer","volume":"10","author":"Pan","year":"2022","journal-title":"Biomark. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: Management of Non-Small-Cell Lung Cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Liu, L., Soler, J., Reckamp, K.L., and Sankar, K. (2024). Emerging Targets in Non-Small Cell Lung Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251810046"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"a037812","DOI":"10.1101\/cshperspect.a037812","article-title":"Molecular Pathology of Lung Cancer","volume":"12","author":"Saller","year":"2022","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107293","DOI":"10.1016\/j.lungcan.2023.107293","article-title":"KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing","volume":"184","author":"Lim","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13353-023-00786-4","article-title":"Modern therapies of nonsmall cell lung cancer","volume":"64","author":"Jachowski","year":"2023","journal-title":"J. Appl. Genet."},{"key":"ref_14","first-page":"300","article-title":"Personalized Treatment for Patients With Lung Cancer","volume":"120","author":"Schuler","year":"2023","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rebuzzi, S.E., Zullo, L., Rossi, G., Grassi, M., Murianni, V., Tagliamento, M., Prelaj, A., Coco, S., Longo, L., and Bello, M.G.D. (2021). Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052625"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wu, J., and Lin, Z. (2022). Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232315056"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2574526","DOI":"10.1080\/07853890.2025.2574526","article-title":"Precision navigation through the labyrinth: Overcoming EGFR resistance in non-Small cell lung cancer","volume":"57","author":"Wang","year":"2025","journal-title":"Ann. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: An update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101586","DOI":"10.1016\/j.esmoop.2023.101586","article-title":"Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: A report from the APODDC working group","volume":"8","author":"Loong","year":"2023","journal-title":"ESMO Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Maione, P., Romano, F.J., and Gridelli, C. (2026). Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?. Curr. Oncol., 33.","DOI":"10.3390\/curroncol33010054"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"108496","DOI":"10.1016\/j.lungcan.2025.108496","article-title":"Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset","volume":"204","author":"Cho","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e20260005","DOI":"10.62958\/j.cjap.2026.005","article-title":"Sunvozertinib A Next-Generation EGFR Exon 20 Insertion Inhibitor Transforming NSCLC Therapy","volume":"42","author":"Kumbhare","year":"2026","journal-title":"Chin. J. Appl. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-016-0251-8","article-title":"Second- and third-generation ALK inhibitors for non-small cell lung cancer","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","article-title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers\u2014Biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo, A., Sobhani, N., Chapman, R., Bagby, S., Bortoletti, C., Traversini, M., Ferrari, K., Voltolini, L., Darlow, J., and Roviello, G. (2020). Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers, 12.","DOI":"10.3390\/cancers12113293"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.24.00731","article-title":"Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non-small cell lung cancer: The phase II TRUST-I study","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"104554","DOI":"10.1016\/j.critrevonc.2024.104554","article-title":"KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies","volume":"205","author":"Liguori","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e35783","DOI":"10.1002\/cncr.35783","article-title":"Advances in the treatment of KRAS(G12C) mutant non-small cell lung cancer","volume":"131","author":"Shaverdashvili","year":"2025","journal-title":"Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1080\/14796694.2024.2407280","article-title":"An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer","volume":"20","author":"Tenekeci","year":"2024","journal-title":"Future Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14796694.2024.2430172","article-title":"Sotorasib for the treatment of locally advanced\/metastatic non-small cell lung cancer","volume":"21","author":"Higgins","year":"2025","journal-title":"Future Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3892\/or.2026.9044","article-title":"Advances in targeting KRAS mutations: A promising approach for the treatment of non-small cell lung cancer (Review)","volume":"55","author":"Sharma","year":"2026","journal-title":"Oncol. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"107886","DOI":"10.1016\/j.lungcan.2024.107886","article-title":"The next-generation KRAS inhibitors\u2026What comes after sotorasib and adagrasib?","volume":"194","author":"Oya","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-med-043024-115849","article-title":"Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer","volume":"77","author":"Lim","year":"2026","journal-title":"Annu. Rev. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Peshin, S., Takrori, E., Yazji, J.H., Haque, J., Dharia, A., Mithani, M.S., Anum, F., Asfeen, U., Couch, J.K., and Donovan, M. (2025). Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311517"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.2147\/OTT.S230309","article-title":"Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer","volume":"12","author":"Guo","year":"2019","journal-title":"Oncol. Targets Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.21037\/jtd-2025-aw-2202","article-title":"Targeting rare oncogenic mutations in resectable non-small cell lung cancer: Emerging perioperative strategies","volume":"18","author":"Hao","year":"2026","journal-title":"J. Thorac. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO-24-01727","article-title":"HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced\/metastatic solid tumors with HER2 alterations: A phase Ia dose-escalation study","volume":"43","author":"Heymach","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer","volume":"393","author":"Le","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/cncr.35423","article-title":"Top advances of the year: Targeted therapy for lung cancer","volume":"130","author":"Makarem","year":"2024","journal-title":"Cancer"},{"key":"ref_54","first-page":"600434","article-title":"Targeted Therapy-Induced Interstitial Lung Disease in NSCLC: Mechanisms, Clinical Signatures, and a Precision Medicine Roadmap","volume":"20","author":"Wang","year":"2026","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ferreira, D., Miranda, J., Martins-Lopes, P., Adega, F., and Chaves, R. (2021). Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083815"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1200\/JCO.2022.40.16_suppl.9002","article-title":"KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced\/metastatic non\u2013small cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"40","author":"Spira","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRASG12C Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e001002","DOI":"10.1136\/bmjonc-2025-001002","article-title":"Circulating-tumour DNA (ctDNA) in NSCLC: Mechanisms, evidence and the future of MRD detection","volume":"5","author":"Urtecho","year":"2026","journal-title":"BMJ Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jclinpath-2021-207490","article-title":"Molecular diagnosis in non-small-cell lung cancer: Expert opinion on ALK and ROS1 testing","volume":"75","author":"Conde","year":"2022","journal-title":"J. Clin. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e70388","DOI":"10.1002\/mco2.70388","article-title":"Transforming Cancer Diagnostics: The Emergence of Liquid Biopsy and Epigenetic Markers","volume":"6","author":"Saha","year":"2025","journal-title":"MedComm"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12951-023-01908-0","article-title":"Metabolomic investigation of urinary extracellular vesicles for early detection and screening of lung cancer","volume":"21","author":"Yang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"216365","DOI":"10.1016\/j.canlet.2023.216365","article-title":"Circulating tumor DNA as liquid biopsy in lung cancer: Biological characteristics and clinical integration","volume":"577","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Casagrande, G.M.S., Silva, M.D., Reis, R.M., and Leal, L.F. (2023). Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032505"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/path.6238","article-title":"Image-based multiplex immune profiling of cancer tissues: Translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer","volume":"262","author":"Jahangir","year":"2024","journal-title":"J. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1097\/CAD.0000000000001242","article-title":"A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance","volume":"33","author":"Qu","year":"2022","journal-title":"Anticancer Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: An update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1007\/s00432-021-03828-8","article-title":"Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: From mechanism analysis to clinical strategy","volume":"147","author":"Zhao","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., and Liu, Y. (2024). Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: Promising strategies to overcoming challenges. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1366260"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Bertoli, E., De Carlo, E., Del Conte, A., Stanzione, B., Revelant, A., Fassetta, K., Spina, M., and Bearz, A. (2022). Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136936"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next Generation EGFR Inhibitors: An Overview of Osimertinib Resistance Mediated by EGFR Mutations in Non-Small Cell Lung Cancer","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"103935","DOI":"10.1016\/j.esmoop.2024.103935","article-title":"Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"9","author":"Li","year":"2024","journal-title":"ESMO Open"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/j.cllc.2021.06.011","article-title":"Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature","volume":"23","author":"Koopman","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/oncolo\/oyae205","article-title":"Advances and future directions in ROS1 fusion-positive lung cancer","volume":"29","author":"Boulanger","year":"2024","journal-title":"Oncologist"},{"key":"ref_76","first-page":"1","article-title":"An insight into lung cancer: A comprehensive review exploring ALK TKI and mechanisms of resistance","volume":"22","author":"Patcas","year":"2022","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Lau, L.Y.E., Skanderup, A.J., and Tan, A.C. (2025). Lineage Plasticity and Histologic Transformation in EGFR-TKI Resistant Lung Cancer. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27010445"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"103966","DOI":"10.1016\/j.critrevonc.2023.103966","article-title":"Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: From preclinical observations to clinical implications","volume":"184","author":"Toyokawa","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Peng, L., Deng, S., Li, J., Zhang, Y., and Zhang, L. (2025). Single-Cell RNA Sequencing in Unraveling Acquired Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: New Perspectives. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041483"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"107885","DOI":"10.1016\/j.lungcan.2024.107885","article-title":"Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer","volume":"194","author":"Izumi","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1111\/cas.16192","article-title":"Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms","volume":"115","author":"Takemura","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"189413","DOI":"10.1016\/j.bbcan.2025.189413","article-title":"Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches","volume":"1880","author":"Liu","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez de C\u00f3rdoba, I., Mielgo-Rubio, X., Cejas, P., Ramos, J.P., Garrido-Rubiales, B., Mart\u00ednez, S.F., Romero, G.R., Parga, M.M., Taltavull, L.M., and Gonz\u00e1lez, A.F. (2025). Transformation to Neuroendocrine Phenotype in Non-Small-Cell Lung Carcinoma: A Literature Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115096"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Zeng, J., Ding, X., Ding, J., and Wang, X. (2023). Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1275957"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"De Lucia, A., Mazzotti, L., Gaimari, A., Zurlo, M., Maltoni, R., Cerchione, C., Bravaccini, S., Delmonte, A., Crin\u00f2, L., and de Souza, P.B. (2025). Non-small cell lung cancer and the tumor microenvironment: Making headway from targeted therapies to advanced immunotherapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1515748"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Gong, X., Zhou, Y., and Deng, Y. (2025). Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug Development. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32070367"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2536786","DOI":"10.1080\/15592294.2025.2536786","article-title":"The role of histone methyltransferases in therapeutic resistance of NSCLC","volume":"20","author":"Zhu","year":"2025","journal-title":"Epigenetics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"103454","DOI":"10.1016\/j.critrevonc.2021.103454","article-title":"Hype or hope\u2014Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced\/metastatic NSCLC?","volume":"166","author":"Papini","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e70921","DOI":"10.1002\/cam4.70921","article-title":"Strategies Beyond 3rd EGFR-TKI Acquired Resistance: Opportunities and Challenges","volume":"14","author":"Zhou","year":"2025","journal-title":"Cancer Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"113959","DOI":"10.1016\/j.biopha.2022.113959","article-title":"The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC","volume":"156","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e20250033","DOI":"10.62958\/j.cjap.2025.033","article-title":"Next-Generation Targeted Therapy: The Evolving Role of Taletrectinib in Fusion-Positive Malignancies","volume":"41","author":"Mankar","year":"2025","journal-title":"Chin. J. Appl. Physiol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Cordani, N., Nova, D., Sala, L., Abbate, M.I., Colonese, F., Cortinovis, D.L., and Canova, S. (2024). Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252011214"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2022.05.011","article-title":"Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies","volume":"170","author":"Johnson","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"100839","DOI":"10.1016\/j.lanepe.2024.100839","article-title":"Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer","volume":"38","author":"Timens","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e012288","DOI":"10.1136\/jitc-2025-012288","article-title":"Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: The role of KEAP1, SMARCA4, and PTEN mutations","volume":"13","author":"Paredes","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Cherukuri, S.P., Kaur, A., Goyal, B., Kukunoor, H.R., Sahito, A.F., Sachdeva, P., Yerrapragada, G., Elangovan, P., Shariff, M.N., and Natarajan, T. (2025). Artificial Intelligence-Enhanced Liquid Biopsy and Radiomics in Early-Stage Lung Cancer Detection: A Precision Oncology Paradigm. Cancers, 17.","DOI":"10.3390\/cancers17193165"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: A systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11684-016-0488-1","article-title":"Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors","volume":"10","author":"Wang","year":"2016","journal-title":"Front. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.soc.2023.12.004","article-title":"Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards","volume":"33","author":"Fujiwara","year":"2023","journal-title":"Surg. Oncol. Clin. North Am."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/9\/1076\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:17:09Z","timestamp":1788769029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/9\/1076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":99,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["genes17091076"],"URL":"https:\/\/doi.org\/10.3390\/genes17091076","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]}}}